No Data
Zhejiang Orient Gene Biotech (688298.SH): obtained the medical instruments registration certificate.
On December 19, Gelonghui reported that Zhejiang Orient Gene Biotech (688298.SH) announced that its wholly-owned subsidiary, USA Hengjian Biotech Co., Ltd., recently obtained the FDA 510(K) license for drug urine cup combined testing reagents (professional/self-testing); Zhejiang Orient Gene's COVID-19/flu A and B antigen triple testing reagents (professional/self-testing) recently obtained the EU IVDR registration certificate. The FDA 510(K) certification obtained by the wholly-owned subsidiary USA Hengjian's drug urine cup combined testing reagents (professional/self-testing) enriches the company's range of drug testing reagents in the USA market and is beneficial.
After investing 1.5 billion over three years to build a Global research and development headquarters, can Zhejiang Orient Gene Biotech win this "turnaround battle"?
① Zhejiang Orient Gene Biotech spent 0.29 billion yuan to acquire land in Zhangjiang, planning to build a global digital research and development innovation headquarters project with a total investment of 1.5 billion yuan, expected to achieve annual sales revenue of 1.5 billion yuan upon reaching production capacity. ② After the demand for nucleic acid testing declined, Zhejiang Orient Gene Biotech encountered a performance "slump", remaining in a net loss of over 260 million yuan until the first three quarters of 2024.
Zhejiang Orient Gene Biotech (688298.SH): Currently, the detection products are not linked to AI-assisted treatment.
On December 3rd, Gelonghui reported that zhejiang orient gene biotech (688298.SH) stated on the interactive platform that the company's testing products are currently not associated with AI-assisted treatment.
Zhejiang orient gene biotech (688298.SH): The company's liquid biochip is currently being promoted in domestic and foreign hospital markets.
gelonlin december 3rd zhejiang orient gene biotech (688298.SH) stated on the interactive platform that the company's liquid biological chip is currently being promoted in the domestic and foreign hospital markets.
Is Zhejiang Orient Gene Biotech (SHSE:688298) Using Debt Sensibly?
Oriental Biotech: third quarter report 2024
Is Zhejiang Orient Gene BiotechLtd (SHSE:688298) Using Debt Sensibly?